Post transplant lymphoproliferative disorder

Post transplant lymphoproliferative disorder
ICD-O:	M9970/1
DiseasesDB	34154

WikiDoc Resources for Post transplant lymphoproliferative disorder
Articles
Most recent articles on Post transplant lymphoproliferative disorder Most cited articles on Post transplant lymphoproliferative disorder Review articles on Post transplant lymphoproliferative disorder Articles on Post transplant lymphoproliferative disorder in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Post transplant lymphoproliferative disorder Images of Post transplant lymphoproliferative disorder Photos of Post transplant lymphoproliferative disorder Podcasts & MP3s on Post transplant lymphoproliferative disorder Videos on Post transplant lymphoproliferative disorder
Evidence Based Medicine
Cochrane Collaboration on Post transplant lymphoproliferative disorder Bandolier on Post transplant lymphoproliferative disorder TRIP on Post transplant lymphoproliferative disorder
Clinical Trials
Ongoing Trials on Post transplant lymphoproliferative disorder at Clinical Trials.gov Trial results on Post transplant lymphoproliferative disorder Clinical Trials on Post transplant lymphoproliferative disorder at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Post transplant lymphoproliferative disorder NICE Guidance on Post transplant lymphoproliferative disorder NHS PRODIGY Guidance FDA on Post transplant lymphoproliferative disorder CDC on Post transplant lymphoproliferative disorder
Books
Books on Post transplant lymphoproliferative disorder
News
Post transplant lymphoproliferative disorder in the news Be alerted to news on Post transplant lymphoproliferative disorder News trends on Post transplant lymphoproliferative disorder
Commentary
Blogs on Post transplant lymphoproliferative disorder
Definitions
Definitions of Post transplant lymphoproliferative disorder
Patient Resources / Community
Patient resources on Post transplant lymphoproliferative disorder Discussion groups on Post transplant lymphoproliferative disorder Patient Handouts on Post transplant lymphoproliferative disorder Directions to Hospitals Treating Post transplant lymphoproliferative disorder Risk calculators and risk factors for Post transplant lymphoproliferative disorder
Healthcare Provider Resources
Symptoms of Post transplant lymphoproliferative disorder Causes & Risk Factors for Post transplant lymphoproliferative disorder Diagnostic studies for Post transplant lymphoproliferative disorder Treatment of Post transplant lymphoproliferative disorder
Continuing Medical Education (CME)
CME Programs on Post transplant lymphoproliferative disorder
International
Post transplant lymphoproliferative disorder en Espanol Post transplant lymphoproliferative disorder en Francais
Business
Post transplant lymphoproliferative disorder in the Marketplace Patents on Post transplant lymphoproliferative disorder
Experimental / Informatics
List of terms related to Post transplant lymphoproliferative disorder

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Post-transplant lymphoproliferative disorder (PTLD) is the name given to a group of B cell lymphomas occurring in immunosuppressed patients following organ transplant.

Incidence/prevalence

It is an uncommon condition occurring in 0.2% of patients within one year of transplant, with an annual incidence of 0.04% thereafter. The risk of developing the disease is higher in children and recipients of heart transplants.

Causes

The disease is an uncontrolled proliferation of B cell lymphocytes following infection with Epstein-Barr virus. Production of an interleukin-10, an endogenous anti-T cell cytokine, has also been implicated.

In immunocompetent patients, Epstein-Barr virus causes infectious mononucleosis, characterised by a proliferation of B-lymphocytes which is controlled by Suppressor T cells.

However, calcineurin inhibitors (tacrolimus and cyclosporine) used as immunosuppressants in organ transplantation inhibit T cell function, and can prevent the control of the B cell proliferation.

Depletion of T cells by use of anti-T cell antibodies in the prevention or treatment of transplant rejection further increases the risk of developing post-transplant lymphoproliferative disorder. Such antibodies include ATG, ALG and OKT3.

Polyclonal PTLD may form tumor masses and present with symptoms due to a mass effect, e.g. symptoms of bowel obstruction. Monoclonal forms of PTLD tend to form a disseminated malignant lymphoma.

Treatment

PTLD may spontaneously regress on reduction or cessation of immunosuppressant medication, and can also be treated with addition of anti-viral therapy. In some cases it will progress to non-Hodgkin's lymphoma and may be fatal.